Sarepta Therapeutics' (SRPT) stock continued to sink Tuesday, down more than 4% in pre-market trade, following a rough end to ...

Sarepta Therapeutics shares traded lower in premarket trade on Tuesday, as the drugmaker relented to a Food and Drug ...

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

As a result, the market is dumping Sarepta stock, which is down -42% in trading so far today. Sarepta's current market cap valuation has fallen <$6bn, when at the beginning of this week, it had ...

Sarepta stock target cut to $184 by Oppenheimer, ... Oppenheimer’s analysts echoed the sentiment that the market’s reaction to the patient death and the European Medicines Agency’s ...

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on SRPT stock, giving a Buy rating on December 29. Joseph Schwartz ...

What happened Shares of the rare-disease drugmaker Sarepta Therapeutics (NASDAQ: SRPT) crashed and burned in May seemingly due to nothing more than a.

Sarepta Therapeutics' (SRPT) stock continued to sink Tuesday following a rough end to last week, including a previously ...